MULTIPLE SCLEROSIS THERAPEUTICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Multiple Sclerosis Therapeutics Market, By Drug Class (Beta Interferon, Corticosteroids, Monoclonal Antibodies, Antineoplastic Agent, Others), By Route of Administration (Oral, Injection, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In: 01 Apr, 2026
Code: CMI1310
Page number: 148
Formats: Excel and PDF
Industry: Pharmaceutical
- Historical Range : 2020 - 2024
- Base Year : 2025
- Estimated Year : 2026
- Forecast Period : 2026-2033

Table of Contents (Version-2026)

Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Global Multiple Sclerosis Therapeutics Market, By Drug Class
  - Global Multiple Sclerosis Therapeutics Market, By Route of Administration
  - Global Multiple Sclerosis Therapeutics Market, By Distribution Channel
  - Global Multiple Sclerosis Therapeutics Market, By Region
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER’s Analysis
- Merger and Acquisition Scenario
- Industry Trends
Global Multiple Sclerosis Therapeutics Market, By Drug Class, 2021 - 2033, (USD Bn)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2022 - 2033
  - Segment Trends
- Beta Interferon
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Corticosteroids
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Monoclonal Antibodies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Antineoplastic Agent
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Global Multiple Sclerosis Therapeutics Market, By Route of Administration, 2021 - 2033, (USD Bn)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2022- 2033
  - Segment Trends
- Oral
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Injection
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Global Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2022 - 2033
  - Segment Trends
- Hospital Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Global Multiple Sclerosis Therapeutics Market, By Region, 2021 - 2033, (USD Bn)
- Introduction
  - Market Share (%) Analysis, 2026, 2028 & 2033, (USD Bn)
  - Market Y-o-Y Growth Analysis (%), 2022 - 2033, (USD Bn)
  - Regional Trends
- North America
  - Introduction
  - Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
  - Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
  - Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
    - U.S.
    - Canada
- Latin America
  - Introduction
  - Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
  - Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
  - Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
    - Brazil
    - Argentina
    - Mexico
    - Rest of Latin America
- Europe
  - Introduction
  - Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
  - Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
  - Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
    - Germany
    - U.K.
    - Spain
    - France
    - Italy
    - Russia
    - Rest of Europe
- Asia Pacific
  - Introduction
  - Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
  - Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
  - Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - Introduction
  - Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
  - Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
  - Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
    - GCC Countries
    - Israel
    - Rest of Middle East
- Africa
  - Introduction
  - Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
  - Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
  - Market Size and Forecast, By Country/Region, 2021 - 2033, (USD Bn)
    - South Africa
    - North Africa
    - Central Africa
Competitive Landscape
- Biogen Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Novartis AG
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Merck KGaA
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Sanofi S. A.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Acorda Therapeutics, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Teva Pharmaceuticals Industries Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Bristol-Myers Squibb Company
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Bayer AG
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Hoffmann-La Roche AG
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Viatris Inc. (Mylan NV)
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Johnson & Johnson
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- EMD Serono, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- TG Therapeutics, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Genentech, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Celgene Corporation
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- AbbVie Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Amgen Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- UCB S.A.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Sandoz (a Novartis division)
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Ipsen S.A.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
References and Research Methodology
- References
- Research Methodology
- About us

*Browse 32 market data tables and 28 figures on 'Multiple Sclerosis Therapeutics Market' - Global forecast to 2033

Instant Download - Buy Now

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now